Systemic IV Delivery of VSR Lipoprotein Nanoparticles to Revert Pulmonary Hypertension and Vascular Remodeling in Pulmonary Arterial Hypertension Patients.

VSR03

We are developing an IV formulation of LNPs that target and specifically reprogram lung vascular cells (endothelial cells) to modulate the endothelial-to-mesenchymal transition that underlies/ perpetuates/ drives vascular changes and chronic inflammation in pulmonary hypertension. The therapy can be given every 30 days at an outpatient clinic.

Different formulations of the API to enable other routes of delivery are being developed.

VSR05

Systemic IV Delivery of VSR Lipoprotein Nanoparticles to induce regression and stabilization of fatty atherosclerotic plaques (vulnerable atherosclerotic plaques) in cardiovascular patients.

We are developing an IV formulation of LNPs that target and specifically reprogram coronary vascular cells (heart vasculature endothelial cells) and carotid vascular (endothelial) cells to modulate the mechanisms that drives chronic inflammation and vascular clogging/ obstruction in patients with coronary artery disease and cerebrovascular disease. The therapy can be given every 30 days at an outpatient clinic.

Different formulations of the API to enable other routes of delivery are being developed.

If you are interested in learning more about the science behind our technology, check out our selected literature